Eltrombopag shows improved platelet counts and quality-of-life outcomes in treating pediatric immune thrombocytopenia.

The FDA also accepted Sobi’s New Drug Application (NDA) for avatrombopag for oral suspension. Avatrombopag for oral suspension is a capsule where its granules are sprinkled onto a soft food or liquid ...

The US Food and Drug Administration (FDA) has accepted Sobi North America’s avatrombopag (DOPTELET) supplemental new drug ...

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for avatrombopag for the treatment of thrombocytopenia in pediatric patients aged 1 year and older with ...

USA: Findings from the PINES trial suggest that eltrombopag (Promacta) may offer improved outcomes for children with newly ...

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., ...

The annual meeting of the American Society of Hematology was held from Dec. 7 to 10 in San Diego and attracted participants ...

Immune thrombocytopenia is an autoimmune disorder characterized by low numbers of platelets that results in an increased risk of bleeding. Prescription Drug User Fee Act (PDUFA) date or a decision ...

Inflammation is the body's natural response to an infection or injury. When confronted with chronic inflammation, the immune system will increase the production of platelets to aid with the repair of ...

Cyrus Biotechnology announces potent in vivo redosability of an engineered IdeS protease for IgG-driven autoimmune disease.